AE Wealth Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

AE Wealth Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,233	Closed	-$368K	–	2040
2022 Q4	$368K	Sell	3,233 -484	-13%	-$40.2K	﹤0.01%	1415
2022 Q3	$230K	Sell	3,717 -12,574	-77%	-$879K	﹤0.01%	1566
2022 Q2	$1.3M	Buy	16,291 +83	+0.5%	+$7.86K	0.01%	808
2022 Q1	$1.71M	Buy	16,208 +597	+4%	+$58.2K	0.01%	743
2021 Q4	$1.68M	Buy	15,611 +814	+6%	+$88.8K	0.01%	755
2021 Q3	$1.62M	Sell	14,797 -58	-0.4%	-$6.02K	0.01%	712
2021 Q2	$1.39M	Sell	14,855 -957	-6%	-$88.1K	0.01%	731
2021 Q1	$1.46M	Buy	+15,812	New	+$1.33M	0.01%	661

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AE Wealth Management's HZNP Position: Q1 2023 in Review

AE Wealth Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q1 2023, closing a stake of 3,233 shares — an estimated $368K sold.

AE Wealth Management first reported a position in HZNP in Q1 2021 and held it in 8 quarters. The position peaked at $1.71M in Q1 2022. 553 funds tracked by Wall St. Rank hold HZNP as of Q1 2023.

AE Wealth Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q1 2023 after selling out during the quarter.
AE Wealth Management sold 3,233 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q1 2023, an estimated $368K.
AE Wealth Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q1 2021 and held it in 8 quarters.
AE Wealth Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $1.71M in Q1 2022.
553 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q1 2023.

Based on AE Wealth Management's 13F filing for Q1 2023, filed 14 Apr 2023.